Form 4: Aeluma Director Denbaars Sells 25,000 Shares

Aeluma, Inc. Director Steven Denbaars reported the sale of 25,000 shares of common stock over two days in late February 2026, executed under a pre-established 10b5-1 trading plan.

Summary

• Aeluma, Inc. Director Steven Denbaars sold a total of 25,000 shares of common stock.
• The sales occurred on February 25, 2026, and February 26, 2026.
• On February 25, 2026, 12,500 shares were sold at a weighted average price of $17.5813 per share, with prices ranging from $17.11 to $17.97.
• On February 26, 2026, another 12,500 shares were sold at a weighted average price of $15.8475 per share, with prices ranging from $15.475 to $16.41.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Denbaars on November 20, 2025.
• Following these sales, Mr. Denbaars beneficially owns 385,088 shares of Aeluma, Inc. common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal. While the sales were pre-planned, significant insider selling, especially with a declining average price over the selling period, can dampen investor sentiment regarding the company's short-to-medium term prospects.

Positives

• The sales were conducted under a pre-established Rule 10b5-1 trading plan, indicating a planned divestment rather than a reaction to immediate negative news.

Negatives

• A director selling a significant number of shares (25,000) can be perceived negatively by the market, potentially signaling a lack of confidence or a belief that the stock price may not rise significantly in the near term.
• The average sale price on February 26, 2026 ($15.8475), was lower than the average sale price on February 25, 2026 ($17.5813), indicating a declining price during the selling period.

Risks

• The Power of Attorney explicitly states that the Attorneys-in-Fact and the Company assume no liability for the undersigned's responsibility to timely comply with SEC reporting requirements, any failure to comply, or for profit disgorgement under Section 16(b) of the Exchange Act.
• The Power of Attorney does not relieve the undersigned from responsibility for compliance with beneficial ownership and other reporting obligations.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider selling, even when pre-planned via a 10b5-1 plan, can sometimes be interpreted by the market as a signal, particularly if the volume is significant relative to the insider's total holdings or the company's daily trading volume. While 10b5-1 plans are designed to mitigate concerns about opportunistic trading, a director's decision to sell a substantial block of shares might still lead investors to question the near-term growth prospects or valuation of Aeluma, Inc. compared to its peers.

Comparison to Industry Standards

• NA (A Form 4 filing primarily reports individual insider transactions and does not provide sufficient data for a direct comparison to industry-wide financial or operational standards.)

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret the director's selling as a negative signal, potentially leading to decreased confidence or downward pressure on the stock price.
• Management/Employees: Could potentially affect morale if interpreted as a lack of confidence from a director, though the 10b5-1 plan mitigates this to some extent.

Key Dates

Recommendation

While the insider selling is a negative signal, the pre-planned nature of the sales via a 10b5-1 plan suggests it's not a reaction to immediate adverse news. However, the volume of shares sold and the declining average price during the selling period warrant caution. Investors should hold and monitor future insider activity and company performance before making further investment decisions.

Keywords

Aeluma Inc., ALMU, Insider Selling, Form 4, Director Stock Sale, Steven Denbaars, 10b5-1 Plan, Equity Transaction, Corporate Governance